The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Monoclonal antibodies: the future of MM treatment?
Monoclonal antibody therapy has been around for a long while, but recent technological advancements have allowed for more tailored and specific types of monoclonal antibodies to be produced. In this interview, Faith Davies, MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, describes these new types of antibodies, including antibody-drug conjugates (ADCs) and bispecifics, as well as touching upon CAR T-cells. She highlights a specific multiple myeloma antigen, BCMA, which is the target of several new ADCs currently in development. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
